SelvitaWAR:SLV +3.27%81 PB Ratio is 1.83 as of Jun. 27, 2026, which is 66% below its 10-year median of 5.40. GuruFocus rates WAR:SLV with a GF Score™ of 81/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Selvita ranks better than 57.14% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Selvita's share price is zł31.60. Selvita's Book Value per Share for the quarter that ended in Mar. 2026 was zł17.28. Hence, Selvita's PB Ratio of today is 1.83.
Good Sign:
Selvita SA stock PB Ratio (=1.79) is close to 1-year low of 1.66.
The historical rank and industry rank for Selvita's PB Ratio or its related term are showing as below:
WAR:SLV'
s PB Ratio Range Over the Past 10 Years
Min: 1.56 Med: 5.4 Max: 17.42
Current: 1.83
During the past 11 years, Selvita's highest PB Ratio was 17.42. The lowest was 1.56. And the median was 5.40.
WAR:SLV's PB Ratio is ranked better than 57.14% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs WAR:SLV: 1.83
During the past 12 months, Selvita's average Book Value Per Share Growth Rate was -0.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.20% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Selvita was 76.90% per year. The lowest was -9.10% per year. And the median was 24.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Selvita PB Ratio Related Terms
Selvita PB Ratio Historical Data
* Premium members only.
The historical data trend for Selvita's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Selvita's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's PB Ratio distribution charts can be found below:
* The bar in red indicates where Selvita's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Selvita's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Selvita (WAR:SLV) has a PB Ratio of 1.83 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Selvita and its competitors. This is 66% below median its historical median of 5.40. Over the past decade, Selvita's PB Ratio has ranged from 1.56 to 17.42. According to the industry distribution chart, Selvita ranks #84 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 42.9%.
Is Selvita's PB Ratio too high?
Selvita's current PB Ratio of 1.83 is 66% below median its 10-year median of 5.40. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 17.42. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Selvita's value of 1.83 is 10.7% below this industry median. Based on the distribution chart, Selvita ranks #84 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Selvita has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #84 out of 196 companies for PB Ratio. This puts Selvita in the upper half of its industry. The industry median PB Ratio is 2.05. Selvita's value of 1.83 is 10.7% below this benchmark. Historically, Selvita's own PB Ratio has ranged from 1.56 to 17.42 over the past decade. While the company's 10-year median is 5.40 vs. the industry median of 2.05, Selvita has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selvita's current PB Ratio of 1.83 is 10.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Selvita and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current PB Ratio is 1.83, which is 66% below median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current PB Ratio is 1.83, which is 66% below median its 10-year median of 5.40 and 10.7% below the Medical Diagnostics & Research industry median of 2.05. Selvita's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Selvita (WAR:SLV), the current PB Ratio is 1.83 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
PB Ratio: 1.83 (66% below median its 10-year median of 5.40)
GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
Industry Position: 10.7% below the Medical Diagnostics & Research median (#84 of 196)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
81GF Score
Get the complete analysis for WAR:SLV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
